Результаты поиска - Nathanael S. Gray

Отмена результатов
  1. 1
    The rise of degrader drugs

    The rise of degrader drugs по Mingxing Teng, Nathanael S. Gray

    Опубликовано 2023
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    The Evolving War on Cancer

    The Evolving War on Cancer по Daniel A. Haber, Nathanael S. Gray, José Baselga

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Discovery of selective irreversible inhibitors for EGFR-T790M

    Discovery of selective irreversible inhibitors for EGFR-T790M по Wenjun Zhou, Dalia Ercan, Pasi A. Jänne, Nathanael S. Gray

    Опубликовано 2010
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase

    Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase по Roxana E. Iacob, Jianming Zhang, Nathanael S. Gray, John R. Engen

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer

    Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer по Wells S. Brown, Li Tan, Andrew Smith, Nathanael S. Gray, Michael K. Wendt

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Characterization of TAE684 as a potent LRRK2 kinase inhibitor

    Characterization of TAE684 as a potent LRRK2 kinase inhibitor по Jinwei Zhang, Xianming Deng, Hwan Geun Choi, Dario R. Alessi, Nathanael S. Gray

    Опубликовано 2012
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Activation of tyrosine kinases by mutation of the gatekeeper threonine

    Activation of tyrosine kinases by mutation of the gatekeeper threonine по Mohammad Azam, Markus A. Seeliger, Nathanael S. Gray, John Kuriyan, George Q. Daley

    Опубликовано 2008
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    mTOR mediated anti-cancer drug discovery

    mTOR mediated anti-cancer drug discovery по Qingsong Liu, Carson C. Thoreen, Jinhua Wang, David M. Sabatini, Nathanael S. Gray

    Опубликовано 2009
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    A Genome-Wide Overexpression Screen in Yeast for Small-Molecule Target Identification

    A Genome-Wide Overexpression Screen in Yeast for Small-Molecule Target Identification по Hendrik Luesch, Tom Wu, Pingda Ren, Nathanael S. Gray, Peter G. Schultz, František Supek

    Опубликовано 2005
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency по Ultan McDermott, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, Jeff Settleman

    Опубликовано 2010
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 по John M. Hatcher, Eric S. Wang, Liv Johannessen, Nicholas Kwiatkowski, Taebo Sim, Nathanael S. Gray

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells

    Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells по Marta López‐Peláez, Douglas J. Lamont, Mark Peggie, Natalia Shpiro, Nathanael S. Gray, Philip Cohen

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors

    Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors по Peter Canning, Li Tan, Kiki Chu, Sam W. Lee, Nathanael S. Gray, Alex N. Bullock

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

    FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML по Ellen Weisberg, Rosemary Barrett, Qingsong Liu, Richard M. Stone, Nathanael S. Gray, James D. Griffin

    Опубликовано 2009
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  15. 15
    Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

    Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines по Antonio Calles, Nicholas Kwiatkowski, Bernard K. Cammarata, Dalia Ercan, Nathanael S. Gray, Pasi A. Jänne

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

    Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? по Zheng Zhao, Hong Wu, Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu, Nathanael S. Gray

    Опубликовано 2014
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  17. 17
    Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor

    Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor по John M. Hatcher, Jinwei Zhang, Hwan Geun Choi, Genta Ito, Dario R. Alessi, Nathanael S. Gray

    Опубликовано 2015
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

    A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics по A. Chaikuad, Eliana MC Tacconi, J. Zimmer, Yanke Liang, Nathanael S. Gray, Madalena Tarsounas, Stefan Knapp

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Systematic analysis of <scp>BRAF<sup>V</sup></scp><sup>600E</sup> melanomas reveals a role for <scp>JNK</scp>/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis

    Systematic analysis of <scp>BRAF<sup>V</sup></scp><sup>600E</sup> melanomas reveals a role for <scp>JNK</scp>/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis по Mohammad Fallahi‐Sichani, Nathan J. Moerke, Mario Niepel, Tinghu Zhang, Nathanael S. Gray, Peter K. Sorger

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6

    Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6 по Baishan Jiang, Eric S. Wang, Katherine A. Donovan, Yanke Liang, Eric S. Fischer, Tinghu Zhang, Nathanael S. Gray

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: